Marisa C Mizus1, Eleni Tiniakou2. 1. Department of Medicine, Division of Rheumatology, Mason Lord, Center Tower, Johns Hopkins University School of Medicine, 5200 Eastern Avenue, Baltimore, MD, 21224, USA. mmizus1@jhmi.edu. 2. Department of Medicine, Division of Rheumatology, Mason Lord, Center Tower, Johns Hopkins University School of Medicine, 5200 Eastern Avenue, Baltimore, MD, 21224, USA. etiniak1@jhmi.edu.
Abstract
PURPOSE OF REVIEW: The use of lipid-lowering therapies in patients with idiopathic inflammatory myopathies (IIM) is complicated and there are no guidelines for diagnosing, monitoring, or treating atherosclerotic cardiovascular disease (ASCVD) in this group of patients. RECENT FINDINGS: The use of lipid-lowering therapies, especially statins, is recommended in patients with increased risk for ASCVD, which includes patients with inflammatory diseases, based on recent American College of Cardiology/American Heart Association (ACC/AHA) guidelines for ASCVD management. There is accumulating evidence that patients with IIM are at increased risk for ASCVD, similar to other inflammatory diseases. Lipid-lowering therapies have side effects that may be pronounced or confounding in myositis patients, potentially limiting their use. Statins are specifically contraindicated in patients with anti 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) antibodies. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have been shown to be safe and potentially beneficial in patients with IIM. Here, we propose a framework for (1) ASCVD risk assessment and treatment based on ACC/AHA ASCVD primary prevention guidelines; (2) myositis disease monitoring while undergoing lipid-lowering therapy; and (3) management of statin intolerance, including, indications for the use of PCSK9 inhibitors.
PURPOSE OF REVIEW: The use of lipid-lowering therapies in patients with idiopathic inflammatory myopathies (IIM) is complicated and there are no guidelines for diagnosing, monitoring, or treating atherosclerotic cardiovascular disease (ASCVD) in this group of patients. RECENT FINDINGS: The use of lipid-lowering therapies, especially statins, is recommended in patients with increased risk for ASCVD, which includes patients with inflammatory diseases, based on recent American College of Cardiology/American Heart Association (ACC/AHA) guidelines for ASCVD management. There is accumulating evidence that patients with IIM are at increased risk for ASCVD, similar to other inflammatory diseases. Lipid-lowering therapies have side effects that may be pronounced or confounding in myositispatients, potentially limiting their use. Statins are specifically contraindicated in patients with anti 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) antibodies. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have been shown to be safe and potentially beneficial in patients with IIM. Here, we propose a framework for (1) ASCVD risk assessment and treatment based on ACC/AHA ASCVD primary prevention guidelines; (2) myositis disease monitoring while undergoing lipid-lowering therapy; and (3) management of statin intolerance, including, indications for the use of PCSK9 inhibitors.
Authors: G B John Mancini; A Yashar Tashakkor; Steven Baker; Jean Bergeron; David Fitchett; Jiri Frohlich; Jacques Genest; Milan Gupta; Robert A Hegele; Dominic S Ng; Glen J Pearson; Janet Pope Journal: Can J Cardiol Date: 2013-09-29 Impact factor: 5.223
Authors: Cynthia S Crowson; Sherine E Gabriel; Anne Grete Semb; Piet L C M van Riel; George Karpouzas; Patrick H Dessein; Carol Hitchon; Virginia Pascual-Ramos; George D Kitas Journal: Rheumatology (Oxford) Date: 2017-07-01 Impact factor: 7.580
Authors: Alfonso Corrales; José A Parra; Carlos González-Juanatey; Javier Rueda-Gotor; Ricardo Blanco; Javier Llorca; Miguel A González-Gay Journal: Ann Rheum Dis Date: 2013-07-13 Impact factor: 19.103
Authors: Peter H Jones; Michael H Davidson; Evan A Stein; Harold E Bays; James M McKenney; Elinor Miller; Valerie A Cain; James W Blasetto Journal: Am J Cardiol Date: 2003-07-15 Impact factor: 2.778
Authors: Paul S Phillips; Richard H Haas; Sergei Bannykh; Stephanie Hathaway; Nancy L Gray; Bruce J Kimura; Georgirene D Vladutiu; John D F England Journal: Ann Intern Med Date: 2002-10-01 Impact factor: 25.391
Authors: Vasilios G Athyros; Konstantinos Tziomalos; Anna I Kakafika; Haralambos Koumaras; Asterios Karagiannis; Dimitri P Mikhailidis Journal: Am J Cardiol Date: 2007-12-20 Impact factor: 2.778
Authors: Russell Scott; Richard O'Brien; Greg Fulcher; Chris Pardy; Michael D'Emden; Dana Tse; Marja-Riitta Taskinen; Christian Ehnholm; Anthony Keech Journal: Diabetes Care Date: 2008-11-04 Impact factor: 19.112